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The addition of polysialic acid to N-and/or O-linked glycans, referred to as polysialylation, is a rare posttranslational modification that is mainly known to control the developmental plasticity of the nervous system. Here we show that CCR7, the central chemokine receptor controlling immune cell trafficking to secondary lymphatic organs, carries polysialic acid. This modification is essential for the recognition of the CCR7 ligand CCL21. As a consequence, dendritic cell trafficking is abrogated in polysialyltransferase-deficient mice, manifesting as disturbed lymph node homeostasis and unresponsiveness to inflammatory stimuli. Structure-function analysis of chemokine-receptor interactions reveals that CCL21 adopts an autoinhibited conformation, which is released upon interaction with polysialic acid. Thus, we describe a glycosylation-mediated immune cell trafficking disorder and its mechanistic basis.
P olysialylation is a rare posttranslational modification executed by the two enzymes ST8Sia II and ST8Sia IV (1) . These polysialyltransferases generate long a2,8-linked linear homopolymers of sialic acid, which are attached to N-and/or O-linked glycans (2) . Polysialylation is mainly known to control the developmental plasticity of the vertebrate nervous system by modulating cell-cell and cellmatrix adhesions (3). Polysialic acid (polySia) further promotes cancer growth and metastasis through largely unknown mechanisms (4, 5) and, as such, is pursued as a therapeutic target (6) . Recent evidence also suggests various functional implications during immune responses (7) (8) (9) (10) .
We immunologically characterized mice lacking ST8Sia IV (11), the polysialyltransferase expressed in hematopoietic cells. Under steady-state conditions, mutant animals showed severely reduced cellularity of peripheral lymph nodes (LNs) (Fig. 1A) and frequently lacked small popliteal LNs (10 LNs missing out of 16 expected). Infliction of inflammatory stimuli in mutant and control mice failed to trigger LN swelling in the former (Fig. 1B) . In contrast, cellularity of the spleen did not differ significantly between control and mutant mice (Fig. 1A) , which might indicate specific defects in lymphocyte homing to LNs. However, we could not detect polySia on the surface of T and B cells, and we did not observe any cell-autonomous trafficking defects in the lymphocyte compartment ( fig. S1, A and B) . In contrast, polySia was readily detectable on the surface of dendritic cells (DCs) during steadystate conditions (Fig. 1C, upper panel, and fig.  S1C ), and it was additionally elevated upon inflammatory stimulation (Fig. 1C, lower panel) . LNs of St8sia4-deficient mice contained reduced amounts of DC subsets known to migrate from peripheral tissues into the LNs (Fig. 1D) . Although DCs constitute only~1% of cells in the LNs, they control LN size by instructing stromal cells to recruit lymphocytes and maintain their homeostasis (12, 13) . Hence, a reduced size of the DC compartment might provide a potential explanation for reduced overall LN size. To test whether defective migration from the periphery was responsible for reduced DC numbers in LNs, we performed skin-painting experiments, in which endogenous DCs of the skin are mobilized and subsequently migrate, via the afferent lymphatic vessels, into the draining LN (14) . In St8sia4-deficient mice, migration of DCs into draining LNs was almost completely abrogated (Fig. 1E) .
We next used an in vitro reconstituted system to measure the migratory potential of polySiadeficient DCs. To this end, we generated DCs in vitro from bone marrow precursors. We confirmed that control cells up-regulate polySia upon inflammatory stimulation, whereas St8sia4-deficient cells differentiated normally but completely lacked polySia ( fig. S1D ). When we coinjected control and St8sia4-deficient DCs into the footpads of wild-type recipient mice, polySiadeficient DCs were completely unable to enter the LNs ( Fig. 2A) , formally showing that polySia dependency is cell-autonomous. We next incorporated the in vitro-generated DCs into threedimensional (3D) collagen gels and exposed them to gradients of the chemokines CCL19 and CCL21 (Fig. 2B) . By binding to CCR7, these chemokines guide DCs into the draining LN (15) . Whereas the migratory response toward gradients of CCL19 was equally efficient for control and knockout cells, polySia-deficient DCs were completely refractory to CCL21 (Fig. 2B) . Similarly, signaling, as measured by Akt and extracellular signal-regulated kinase (ERK) phosphorylation, was largely abolished in response to CCL21, whereas the CCL19-triggered signal was comparable to that in control cells ( fig. S2 ). Hence, polySia-deficient DCs were capable of differentiating and migrating regularly but were selectively unresponsive toward CCL21.
En route from the periphery into the LN, CCL21 mediates two key steps: (i) directed interstitial migration toward the dermal lymphatic vessel and (ii) migration from the LN's subcapsular sinus into the deep T cell area. To exclude any confounding effects of CCL19, we probed DC migration in Ccl19-deficient hosts. To bypass the skin and directly measure migration within the LN, we injected DCs into the afferent lymphatic vessel ( fig. S3A ) (16) and control mice were examined by two-tailed unpaired Student's t tests.
polySia-deficient DCs behaved like control cells and entered the deep T cell parenchyma, whereas Ccr7-deficient DCs were unable to leave the subcapsular sinus, as previously shown (Fig. 2C ) (16) . Next, we selectively probed migration within the skin and co-incubated skin explants with polySia-deficient and control DCs. We found that only control cells entered the dermal lymphatic vessels, whereas polySia-deficient DCs did not even infiltrate the dermal interstitium (Fig. 2D) , therefore precisely phenocopying Ccr7-deficient DCs (17) . Similarly, in cultured ear explants of St8sia4-deficient mice, DCs remained in the interstitium and failed to enter the lumen of lymphatic vessels, in contrast to DCs in control tissue ( fig. S3B ). Hence, DCs require polySia to sense dermal CCL21, whereas sensing of LN CCL21 is independent of polySia. Tissue context-specific presentation of CCL21 might explain why T cells, which do not express polySia, are able to home into LNs of Ccl19-deficient mice (18), although they only responded to CCL19 and not to CCL21, when exposed to soluble chemokine ( fig. S3C ). This prompted us to study the molecular mechanism underlying polySia-dependent CCL21 sensing. Although the chemokine domain of CCL21 is structurally similar to that of CCL19 (19, 20) , CCL21 carries a positively charged C-terminal extension, which mediates binding to glycans, particularly heparan sulfate residues (21) . It has been suggested that, via these residues, CCL21 might also interact with negatively charged polySia (9) . Consequently, cell surface polySia might act as a co-receptor and increase the local availability of CCL21 for CCR7 (22) . Of the seven proteins that were described as polySia carriers (2), only neuropilin-2 was expressed on mature DCs (7, 23) fig. S4, A and B) . Because neuropilin-2-deficient DCs still carried polySia, we immunoprecipitated polySia from lysates of mature DCs and used mass spectrometry to identify the underlying protein scaffold(s). This unbiased approach revealed three previously unknown putative polySia carriers, including CCR7 ( fig. S4C and table S1 ). CCR7 and neuropilin-2 emerged as the only candidate molecules exposed on the cell surface.
This suggests that, apart from neuropilin-2, CCR7 is a second polySia carrier on the surface of mature DCs. To further investigate CCR7 as a direct target of polysialylation, we used a human embryonic kidney (HEK) 293 cell system. When green fluorescent protein (GFP) was immunoprecipitated from lysates of cells coexpressing a CCR7-GFP fusion protein and ST8Sia IV, polySia could be detected in the precipitate, whereas it was absent in precipitates of both single transfectants (Fig. 3A) . Vice versa, precipitation of polySia revealed CCR7-GFP specifically in the double transfectants (Fig. 3B) . Further biochemical and mutational analysis in HEK293 cells indicated that polySia was attached to both the Nand O-linked glycans of CCR7, because inhibition of either N-or O-glycosylation did not fully abrogate polysialylation of CCR7 ( fig. S4 , D and E). To substantiate that CCR7 is polysialylated in DCs, we used flow cytometry to analyze cell-surface levels of polySia in Ccr7-deficient and control DCs and found reduced polySia on Ccr7-deficient cells (Fig. 3C ). This further suggests that, apart from neuropilin-2, CCR7 is a second carrier of polySia on the surface of mature DCs.
A co-receptor model would predict that polySia on CCR7 might bind CCL21's C terminus, thereby effectively increasing receptor-to-ligand affinity. To test this idea, we C-terminally truncated CCL21 and performed chemotaxis assays. At odds with a co-receptor model, the responsiveness of polySiadeficient DCs to CCL21 was restored when the chemokine was C-terminally truncated (Fig. 4A) . This finding indicated that, rather than enhancing CCR7 binding to CCL21, the polySia-CCL21 interaction might promote signaling by releasing CCL21 from an otherwise inactive state. This would be consistent with an autoinhibition model, in which the C terminus of CCL21 induces structural alterations within the chemokine domain that prevent signaling but that can be reversed upon polySia binding.
CCL21's C terminus is unstructured and does not adopt a stable fold (20) . We therefore performed nuclear magnetic resonance spectroscopy to detect chemical shifts that might distinguish the chemokine domain conformation of full-length CCL21 from that of C-terminally truncated CCL21. As expected, truncation caused chemical shift changes in residues with immediate proximity to the truncation site ( fig. S5A ). However, additional chemical shifts localized to the a-helix of the chemokine domain (residues 63, 64, 66, 67, 69, and 70) and to additional residues (26, 31, 41, 47, and 54; Fig. 4B and fig. S5A ). These shift perturbations distal to the site of truncation suggest that CCL21's C terminus transiently interacts with the chemokine domain of CCL21, thereby providing a putative structural correlate of functional autoinhibition. When polySia was titrated to full-length CCL21, residues belonging to the putative autoinhibition signature shifted to positions similar to those observed in the spectra of truncated CCL21 (Fig. 4C and fig. S5B ). Hence, in the presence of polySia, the chemokine domain of full-length CCL21 adopts a similar conformation as that of C-terminally truncated CCL21. PolySia binding to truncated CCL21 was considerably weaker than to full-length CCL21, confirming that interactions mainly take place via the C terminus ( fig. S5C ). Together, these data suggest that CCL21's C terminus structurally alters its chemokine domain, probably by transient binding, and that this structural alteration is abrogated by polySia binding to CCL21's C-terminal extension.
To functionally challenge the autoinhibition model, we took advantage of the fact that the polySia-insensitive chemokine CCL19 naturally lacks a C-terminal extension and produced a recombinant chemokine with CCL21's C terminus transplanted to CCL19 (Fig. 4D, right panel) . Chemotaxis assays revealed that control DCs responded to the chimeric chemokine with kinetics that were more similar to those observed for CCL21 than for CCL19 (Fig. 4D, left panel) . The maximal directed response of wild-type DCs toward the chimera was slightly diminished in comparison with the response toward CCL19. Most relevantly, transplantation of CCL21's C terminus to CCL19 conferred polySia sensitivity, because the response of polySia-deficient DCs to the chimeric chemokine was largely abrogated. These data corroborate a model in which polySia releases CCL21 from an autoinhibited state by interacting with CCL21's C terminus.
We have described here a glycosylationdependent immune cell trafficking defect and its underlying molecular mode of action. The polySiadependent release of CCL21 autoinhibition is a mechanism of chemokine regulation that is likely to be relevant for other chemokines that have similar C-terminal extensions. The finding that polySia dependency is restricted to the skin suggests that, depending on the molecular context, CCL21 can either be present in the autoinhibited or the active form. The mechanism that we describe also illuminates how glycosylation of a G protein-coupled receptor allows discrimination between two alternative ligands. Apart from being the key coordinator of adaptive immune cell trafficking, the CCR7 axis is also centrally involved in the spread of metastatic tumors, suggesting that our findings may be therapeutically relevant. 
